Inactive Instrument

Highlights Mylan Inc Nasdaq

Equities

US6285301072

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Jul. 03	Viatris Divests Over-the-Counter Business to Cooper Consumer Health	MT
Jul. 03	Cooper Consumer Health SAS completed the acquisition of Substantially All of the Over-the-Counter Business of Viatris Inc..	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Viatris Divests Over-the-Counter Business to Cooper Consumer Health	Jul. 03	MT
Cooper Consumer Health SAS completed the acquisition of Substantially All of the Over-the-Counter Business of Viatris Inc..	Jul. 02	CI
Viatris Says US Department of Justice's Antitrust Division No Longer Considers Mylan Subject of Investigation	Jul. 02	MT
US DOJ drops Viatris unit Mylan from industry-wide antitrust probe	Jul. 02	RE
US DOJ informs Viatris' Mylan is no longer part of antitrust investigation	Jul. 02	RE
European Commission Conditionally Approves Cooper-Viatris Deal	Jun. 27	MT
IQuest Enterprises Private Limited acquired API operations of Viatris in India.	Jun. 02	CI
Ex-dividend day	May. 22	FA
Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022.	May. 09	CI
Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024	May. 09	CI
Viatris Inc. Revises Earnings Guidance for the Year 2024	May. 09	CI
Viatris' Q1 Adjusted Earnings, Revenue Decrease; 2024 Outlook Reduced	May. 09	MT
(VTRS) VIATRIS Forecasts Fiscal Year 2024 Revenue Range $14.98B - $15.48B	May. 09	MT
Earnings Flash (VTRS) VIATRIS Posts Q1 Revenue $3.66B, vs. Street Est of $3.69B	May. 09	MT
Earnings Flash (VTRS) VIATRIS Reports Q1 EPS $0.67, vs. Street Est of $0.67	May. 09	MT
Viatris Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Viatris' Proposed Femoston, Duphaston UK Rights Divestment Being Considered, CMA Says	Apr. 18	MT
UK Regulator to Consider Undertakings for Theramex-Viatris Deal	Apr. 18	MT
Viatris Launches New Generic Treatment Option for Multiple Sclerosis in Canada	Apr. 15	MT
Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada	Apr. 15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Mylan Inc Nasdaq

Equities

US6285301072

Highlights

Filters